Nuvation Bio Transitions To Commercial Stage With Iptrozi And Safusidenib Progress [Yahoo! Finance]
Nuvation Bio Inc. Class A (NUVB)
Company Research
Source: Yahoo! Finance
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Nuvation Bio (NYSE:NUVB) received full U.S. FDA approval for its first oncology therapy, Iptrozi, for advanced ROS1-positive non-small cell lung cancer. The company has commercially launched Iptrozi in the U.S. with early reports of strong adoption. Nuvation Bio entered an exclusive licensing partnership with Eisai for Iptrozi in Europe. The company also finalized a clinical protocol amendment for safusidenib in IDH1-mutant glioma, aligning with an accelerated approval path. Nuvation Bio is moving from a purely clinical-stage story into one with an active commercial product, anchored by Iptrozi's full FDA approval and U.S. launch. Shares recently traded at $4.36, with a 1 year return of 139.6% and a 3 year return of 143.6%, alongside a 49.2% decline year to date. That mix of strong longer term gains and recent weakness sets the backdrop
Show less
Read more
Impact Snapshot
Event Time:
NUVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVB alerts
High impacting Nuvation Bio Inc. Class A news events
Weekly update
A roundup of the hottest topics
NUVB
News
- Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewswire
- Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio (NUVB) had its price target lowered by UBS Group AG from $10.00 to $7.00. They now have a "neutral" rating on the stock.MarketBeat
- Nuvation Bio (NUVB) had its price target raised by Royal Bank Of Canada from $12.00 to $13.00. They now have an "outperform" rating on the stock.MarketBeat
NUVB
Earnings
- 3/2/26 - In-Line
NUVB
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- NUVB's page on the SEC website